title: Alterations in lipid transfer to high-density lipoprotein (HDL) and activity of paraoxonase-1 in HIV+ patients.
abstract: HIV+ patients often develop alterations of the plasma lipids that may implicate in development of premature coronary artery disease. High-density lipoprotein (HDL) has an important role in preventing atherogenesis and the aim of this study was to investigate aspects of HDL function in HIV+ patients. HIV+ patients (n = 48) and healthy control subjects (n = 45) of both sexes with similar age were studied. Twenty-five were not being treated with antiretroviral agents, 13 were under reverse transcriptase inhibitor nucleosidic and non-nucleosidic (NRTI+NNRTI) and 10 were under NRTI + protease inhibitors (NRTI+PI) treatment. Paraoxonase 1 (PON1) activity and the transfer of free and esterified cholesterol, tryglicerides and phospholipids from a lipidic nanoemulsion to HDL were analyzed. In comparison with healthy controls, HIV+ patients presented low PON-1 activity and diminished transfer of free cholesterol and tryglicerides. In contrast, phospholipid transfer was increased in those patients, whereas the transfer of cholesteryl esters was unchanged. NRTI+NNRTI increases the transfer of cholesteryl esters and triglycerides but in NRTI+PI there was no difference in respect to non-treated HIV+ patients. HDL from HIV+ patients has smaller antioxidant properties, as shown by lower PON-1 activity, and the transfer of lipids to this lipoprotein fraction is also altered, suggesting that HDL function is defective in those patients.
authors.affiliation: Faculty of Pharmaceutical Sciences, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
authors.forename: Elaine Nunes
authors.initials: EN
authors.lastname: Daminelli
authors.forename: Celso
authors.initials: C
authors.lastname: Spada
authors.forename: Arício
authors.initials: A
authors.lastname: Treitinger
authors.forename: Tatiane Vanessa
authors.initials: TV
authors.lastname: Oliveira
authors.forename: Maria da Conceição
authors.initials: Mda C
authors.lastname: Latrilha
authors.forename: Raul Cavalcante
authors.initials: RC
authors.lastname: Maranhão
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D043303:Aryldialkylphosphatase / Q000378:metabolism*; D016022:Case-Control Studies; D002788:Cholesterol Esters / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000201:enzymology* / Q000503:physiopathology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D050356:Lipid Metabolism / Q000502:physiology*; D008075:Lipoproteins, HDL / Q000378:metabolism* / Q000502:physiology; D008297:Male; D010743:Phospholipids / Q000378:metabolism; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D014280:Triglycerides / Q000378:metabolism
chemical_list: D044966:Anti-Retroviral Agents; D002788:Cholesterol Esters; D017320:HIV Protease Inhibitors; D008075:Lipoproteins, HDL; D010743:Phospholipids; D018894:Reverse Transcriptase Inhibitors; D014280:Triglycerides; D043303:Aryldialkylphosphatase